logo
2 Cash-Heavy Stocks Worth Your Attention and 1 to Approach with Caution

2 Cash-Heavy Stocks Worth Your Attention and 1 to Approach with Caution

Yahoo29-04-2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
Financial flexibility is valuable, but it's not everything - at StockStory, we help you find the stocks that can not only survive but also outperform. That said, here are two companies with net cash positions that balance growth with stability and one with hidden risks.
Net Cash Position: $409.1 million (33.1% of Market Cap)
Serving as the guardian of some of medicine's most valuable materials, Azenta (NASDAQ:AZTA) provides biological sample management, storage, and genomic services that help pharmaceutical and biotechnology companies preserve and analyze critical research materials.
Why Do We Avoid AZTA?
Customers postponed purchases of its products and services this cycle as its revenue declined by 6.5% annually over the last five years
Earnings per share have dipped by 9% annually over the past five years, which is concerning because stock prices follow EPS over the long term
Negative free cash flow raises questions about the return timeline for its investments
Azenta's stock price of $26.83 implies a valuation ratio of 52.4x forward price-to-earnings. To fully understand why you should be careful with AZTA, check out our full research report (it's free).
Net Cash Position: $22.05 million (6.5% of Market Cap)
Founded when its founder patented a unique design for a vacuum system used in the sugar refining process, Graham (NYSE:GHM) provides vacuum and heat transfer equipment for the energy, petrochemical, refining, and chemical sectors.
Why Is GHM a Good Business?
Impressive 17% annual revenue growth over the last five years indicates it's winning market share this cycle
Earnings per share have massively outperformed its peers over the last two years, increasing by 298% annually
Free cash flow margin jumped by 5.6 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
At $30.50 per share, Graham Corporation trades at 25.8x forward price-to-earnings. Is now the right time to buy? See for yourself in our comprehensive research report, it's free.
Net Cash Position: $555.2 million (47% of Market Cap)
Pioneering a vertical-scrolling format optimized for mobile devices, WEBTOON Entertainment (NASDAQ:WBTN) operates a global platform where creators publish serialized web-comics and web-novels that users can read in bite-sized episodes.
Why Are We Positive On WBTN?
Market share has increased this cycle as its 11.8% annual revenue growth over the last two years was exceptional
Estimated revenue growth of 8% for the next 12 months implies its momentum over the last two years will continue
Earnings growth has massively outpaced its peers over the last one years as its EPS has compounded at 107% annually
WEBTOON is trading at $9.10 per share, or 9.5x forward EV-to-EBITDA. Is now the time to initiate a position? Find out in our full research report, it's free.
Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.
Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Axon (+711% five-year return). Find your next big winner with StockStory today for free.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval

Yahoo

time10 minutes ago

  • Yahoo

Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval

Mesoblast experienced a 15% increase in its share price over the past week, largely driven by a significant orphan-drug approval by the U.S. FDA for Ryoncil. This approval, granting seven years of exclusivity for a vital treatment, likely bolstered investor confidence given the strengthened competitive positioning of Mesoblast. While broader market trends saw the S&P 500 and Nasdaq reach new highs amid positive investor sentiment on U.S.-China trade discussions, Mesoblast's specific gains were more tied to its unique developments, as they provided a substantial boost, counterbalancing broader market movements. You should learn about the 1 warning sign we've spotted with Mesoblast. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Over the past three years, Mesoblast's total shareholder return, including share price changes and dividends, reached 181.00%. Despite recent gains driven by the U.S. FDA's orphan-drug approval for Ryoncil, the company's one-year performance outpaced the broader Australian Biotechs industry, which returned 12.3% less in the same timeframe. This highlights significant investor confidence and a positive reception to recent strategic advancements. While Mesoblast's share price has experienced impressive growth, it still trades at approximately 88% below consensus analyst price targets. The approval of Ryoncil positions the company competitively, potentially boosting future revenue, as evidenced by the expanded insurance coverage to 104 million U.S. lives. However, Mesoblast remains unprofitable, with A$47.93 million in net losses reported in its recent earnings. Analysts forecast substantial revenue growth at 56.7% annually, but profit forecasts show continued challenges for the next three years. The stock's recent appreciation reflects increased optimism, although the gap between the current share price and targeted fair value suggests room for further market adjustments. Our comprehensive valuation report raises the possibility that Mesoblast is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:MSB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SailPoint, Inc. (SAIL) Receives a Rating Update from a Top Analyst
SailPoint, Inc. (SAIL) Receives a Rating Update from a Top Analyst

Business Insider

time18 minutes ago

  • Business Insider

SailPoint, Inc. (SAIL) Receives a Rating Update from a Top Analyst

TD Cowen analyst Shaul Eyal maintained a Buy rating on SailPoint, Inc. (SAIL – Research Report) today. The company's shares closed today at $22.53. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Eyal is a top 25 analyst with an average return of 26.7% and a 69.56% success rate. Eyal covers the Technology sector, focusing on stocks such as Cloudflare, SailPoint, Inc., and Check Point. In addition to TD Cowen, SailPoint, Inc. also received a Buy from Barclays's Saket Kalia in a report issued on June 3. However, today, Mizuho Securities reiterated a Hold rating on SailPoint, Inc. (NASDAQ: SAIL). SAIL market cap is currently $10.94B and has a P/E ratio of -17.86. Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SAIL in relation to earlier this year.

NVIDIA (NVDA) Gets Buy Rating as AI Data Center Demand Surges Past $50 Billion
NVIDIA (NVDA) Gets Buy Rating as AI Data Center Demand Surges Past $50 Billion

Yahoo

time22 minutes ago

  • Yahoo

NVIDIA (NVDA) Gets Buy Rating as AI Data Center Demand Surges Past $50 Billion

NVIDIA Corporation (NASDAQ:NVDA) is one of the 10 AI Stocks on Wall Street's Radar. One of the most notable analyst calls on Tuesday, June 10, was for NVIDIA Corporation (NASDAQ:NVDA). Bank of America reiterated the stock as 'Buy,' stating that data center demand trends remain robust for Nvidia. 'Developing AI infrastructure leveraging local datasets and workforces is a rapidly growing global phenomenon and we expect it to contribute $50bn+ annually or 10%+ of long-term AI addressable market.' A powerful aerial view of the company's data center, exemplifying the digital services and informatics being offered. In other latest news, Nvidia Corporation and Hewlett-Packard Enterprise said on Tuesday that they are partnering with the Leibniz Supercomputing Centre to build a new supercomputer using Nvidia's next-generation chips. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store